SENATOR MCCORMICK CELEBRATES ELI LILLY’S $3.5 BILLION INVESTMENT IN THE LEHIGH VALLEY

FOGELSVILLE, PA - U.S. Senator Dave McCormick (R-PA) today celebrated Eli Lilly and Company's announcement of a $3.5 billion pharmaceutical manufacturing facility in Fogelsville, Pennsylvania, in the Lehigh Valley. The investment is expected to create 850 high-paying permanent jobs and approximately 2,000 construction jobs, further strengthening Pennsylvania's position as a national leader in life sciences, innovation, and advanced manufacturing.

"Lilly's $3.5 billion investment in the Lehigh Valley is another major win for Pennsylvania, bringing 850 high-paying jobs, strengthening American manufacturing, and cementing the Commonwealth's position as a leader in life sciences," said Senator McCormick. "When I talk about building a pro-growth environment in Pennsylvania, this is the type of investment I am working to attract."

Senator McCormick is proud to have worked alongside Eli Lilly Chairman and CEO David A. Ricks and the Governor to help bring this significant investment to the Lehigh Valley. The project represents another major step toward expanding Pennsylvania's economy, attracting private-sector investment, and creating new opportunities for Pennsylvania workers and families.

The facility will produce next-generation injectable medicines using advanced technologies, including AI and automation. It is expected to be operational by 2031. As part of the investment, Lilly also plans to provide up to $1 million over five years to the Upper Macungie Township Community Fund to support community programs focused on nutrition, healthy living, access to fresh food, and other health resources. The Lehigh Valley facility is part of Lilly's broader $50 billion commitment to expanding pharmaceutical manufacturing sites the company has announced since 2020.

###